TY - JOUR
T1 - ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study
AU - Ceconi, C
AU - Fox, KM
AU - Remme, WJ
AU - Simoons, ML
AU - Deckers, JW
AU - Bertrand, M
AU - Parrinello, G
AU - Kluft, C
AU - Blann, Andrew
AU - Cokkinos, D
AU - Ferrari, R
PY - 2009/5/1
Y1 - 2009/5/1
N2 - The PERTINENT study measured biomarkers of atherosclerosis and thrombosis in a stable coronary artery disease population from EUROPA receiving ACE inhibition with perindopril 8 mg/day or placebo. Biomarkers of inflammation, C-reactive protein (CRP), fibrinogen, and tumor necrosis factor-alpha (TNF-alpha), and a biomarker of thrombosis, D-dimer, were measured at baseline and 1 year. CRP was recorded in 1157 patients; fibrinogen, TNF-alpha, and D-dimer in 291 patients. There was no significant effect of treatment on CRP or fibrinogen. In contrast, there were significant reductions in TNF-alpha (27.60-25.20 pg/mL; P
AB - The PERTINENT study measured biomarkers of atherosclerosis and thrombosis in a stable coronary artery disease population from EUROPA receiving ACE inhibition with perindopril 8 mg/day or placebo. Biomarkers of inflammation, C-reactive protein (CRP), fibrinogen, and tumor necrosis factor-alpha (TNF-alpha), and a biomarker of thrombosis, D-dimer, were measured at baseline and 1 year. CRP was recorded in 1157 patients; fibrinogen, TNF-alpha, and D-dimer in 291 patients. There was no significant effect of treatment on CRP or fibrinogen. In contrast, there were significant reductions in TNF-alpha (27.60-25.20 pg/mL; P
U2 - 10.1016/j.atherosclerosis.2008.08.042
DO - 10.1016/j.atherosclerosis.2008.08.042
M3 - Article
C2 - 18950770
VL - 204
SP - 273
EP - 275
JO - Atherosclerosis
JF - Atherosclerosis
IS - 1
ER -